Physician profile
Daniel Lubelski
NPI 1902290836
$66,743.78
in general payments reported to CMS, 2019-2025
9 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.79 · 2022: $2,288 · 2023: $2,625 · 2024: $20K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $53K · Travel and Lodging: $10K · Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $52,574.30 |
| Travel and Lodging | $10,276.29 |
| Food and Beverage | $1,581.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $32,964.50 | 2022-2025 | Excelsiusgps Robotic Navigation System, Xlif, Excelsius Gps |
| Dilon Technologies, INC. | $10,661.77 | 2025 | Hemoblast Bellows |
| Ethicon US, LLC | $8,049.50 | 2025 | Surgicel Nu-Knit, Vistaseal, Ethicon |
| Depuy Synthes Products, INC. | $6,927.58 | 2025 | Emphasys, Velys |
| Kuros Biosciences USA, INC | $6,454.93 | 2021-2024 | Magnetos |
| Medical Device Business Services, INC. | $1,033.46 | 2022-2025 | |
| Carbofix Spine INC | $361.97 | 2023 | |
| Axogen | $149.24 | 2024 | Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector, Axoguard Nerve Cap |
| Medtronic, INC. | $140.83 | 2023 | Unid_pass |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lubelski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.